Influenza A virus, inactivated hemagglutinin
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2007
- First approval year
- 2007
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Influenza A virus, inactivated hemagglutinin
- influenza a virus inactivated hemagglutinin component of aflunov
- influenza a virus inactivated hemagglutinin component of celldemic
- influenza a virus inactivated hemagglutinin component of fluad tetra
- influenza a virus inactivated hemagglutinin component of flucelvax tetra
- influenza a virus inactivated hemagglutinin component of focetria
- influenza a virus inactivated hemagglutinin component of foclivia
- influenza a virus inactivated hemagglutinin component of incellipan
- influenza a virus inactivated hemagglutinin component of optaflu
- influenza a virus inactivated hemagglutinin component of zoonotic influenza vaccine seqirus
- Influenza a virus, inactivated hemagglutinin component of aflunov
- Influenza a virus, inactivated hemagglutinin component of celldemic
- Influenza a virus, inactivated hemagglutinin component of fluad tetra
- Influenza a virus, inactivated hemagglutinin component of flucelvax tetra
- Influenza a virus, inactivated hemagglutinin component of focetria
- Influenza a virus, inactivated hemagglutinin component of foclivia
- Influenza a virus, inactivated hemagglutinin component of incellipan
- Influenza a virus, inactivated hemagglutinin component of optaflu
- Influenza a virus, inactivated hemagglutinin component of zoonotic influenza vaccine seqirus
- influenza a virus inactivated hemagglutinin
- Influenza a virus, inactivated hemagglutinin
- ChEMBL ID
- CHEMBL6068361
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
Mechanisms of action
- Mechanism
- Hemagglutinin vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Hemagglutinin
- Protein identifier
- P03437
Open Targets mechanisms
- Mechanism
- Hemagglutinin vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Hemagglutinin
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Influenza, Human
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition identifier
- EFO_0007328
- Condition identifier
- EFO_0007411
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 4
- Dose
- 5 pellets
- Route
- Sublingual
- How often
- Three times daily
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (41)
- A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine
- A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
- A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older
- A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults
- Afluria Pregnancy Registry
- Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
- Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older
- Comparison of Three Licensed Influenza Vaccines
- Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression
- Evaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old
- Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers
- First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
- FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care
- Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
- Flucelvax Pregnancy Registry
- Gene Signatures of Influenza Vaccine Responses in Older Adults